Literature DB >> 24375549

Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.

Madeleine E Sharp1, Karen S Marder, Lucien Côté, Lorraine N Clark, William C Nichols, Jean-Paul Vonsattel, Roy N Alcalay.   

Abstract

BACKGROUND: PARKIN-related disease remains incompletely understood. First, the pathogenicity of heterozygous PARKIN mutations is unclear, although some evidence supports causality. Second, unlike sporadic Parkinson's disease (PD), Lewy bodies are present only in a minority of cases. Only one other heterozygote PARKIN carrier with autopsy findings has been described. Our case adds to the broadening pathological and clinical phenotype of PARKIN-related disease.
METHODS: Clinical chart, genetic analysis, and pathological findings of a patient with familial PD are reviewed.
RESULTS: A 44-year-old man developed slowly progressive tremor-predominant PD with excellent response to levodopa. Genetic analysis revealed a heterozygous PARKIN exon 3-4 deletion, also present in 2 family members with early-onset PD. Postmortem examination showed severe neuronal loss in the substantia nigra and nucleus coeruleus with the presence of diffuse Lewy bodies.
CONCLUSIONS: The deletion is unlikely an incidental finding considering family history, age at onset, and the presence of clinical and pathological features not typical of sporadic PD.
© 2013 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Lewy bodies; Parkinson's disease; neuropathology; parkin

Mesh:

Substances:

Year:  2013        PMID: 24375549      PMCID: PMC4281030          DOI: 10.1002/mds.25792

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

1.  Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.

Authors:  R Hilker; C Klein; M Ghaemi; B Kis; T Strotmann; L J Ozelius; O Lenz; P Vieregge; K Herholz; W D Heiss; P P Pramstaller
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

2.  Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Authors:  Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  J Int Neuropsychol Soc       Date:  2010-11-24       Impact factor: 2.892

3.  Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2).

Authors:  Claudio Ruffmann; Michela Zini; Stefano Goldwurm; Manuela Bramerio; Sonia Spinello; Damiana Rusconi; Marcello Gambacorta; Fabrizio Tagliavini; Gianni Pezzoli; Giorgio Giaccone
Journal:  Acta Neuropathol       Date:  2012-05-04       Impact factor: 17.088

4.  Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study.

Authors:  R N Alcalay; A Siderowf; R Ottman; E Caccappolo; H Mejia-Santana; M-X Tang; L Rosado; E Louis; D Ruiz; C Waters; S Fahn; L Cote; S Frucht; B Ford; M Orbe-Reilly; B Ross; M Verbitsky; S Kisselev; C Comella; A Colcher; D Jennings; M Nance; S Bressman; W K Scott; C Tanner; S Mickel; M Rezak; K E Novak; J H Friedman; R Pfeiffer; L Marsh; B Hiner; L N Clark; K Marder
Journal:  Neurology       Date:  2010-12-29       Impact factor: 9.910

5.  Lewy bodies and parkinsonism in families with parkin mutations.

Authors:  M Farrer; P Chan; R Chen; L Tan; S Lincoln; D Hernandez; L Forno; K Gwinn-Hardy; L Petrucelli; J Hussey; A Singleton; C Tanner; J Hardy; J W Langston
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

6.  Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers.

Authors:  Peter P Pramstaller; Michael G Schlossmacher; Thomas S Jacques; Francesco Scaravilli; Cordula Eskelson; Imelda Pepivani; Katja Hedrich; Susanna Adel; Melissa Gonzales-McNeal; Rüdiger Hilker; Patricia L Kramer; Christine Klein
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

7.  Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.

Authors:  N Pankratz; D K Kissell; M W Pauciulo; C A Halter; A Rudolph; R F Pfeiffer; K S Marder; T Foroud; W C Nichols
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

Review 8.  The epidemiology of dementia associated with Parkinson disease.

Authors:  Dag Aarsland; Martin Wilhelm Kurz
Journal:  J Neurol Sci       Date:  2009-09-04       Impact factor: 3.181

9.  The incidence and characteristics of Lewy bodies in idiopathic paralysis agitans (Parkinson's disease).

Authors:  J BETHLEM; W A DEN HARTOG JAGER
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

10.  Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene.

Authors:  Lorraine N Clark; Eneli Haamer; Helen Mejia-Santana; Juliette Harris; Suzanne Lesage; Alexandra Durr; Sabine Janin Bs; Katja Hedrich; Elan D Louis; Lucien J Cote; Howard Andrews; Stanley Fahn; Cheryl Waters; Blair Ford; Steven Frucht; William Scott; Christine Klein; Alexis Brice; Hanno Roomere; Ruth Ottman; Karen Marder
Journal:  Mov Disord       Date:  2007-05-15       Impact factor: 10.338

View more
  9 in total

1.  The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Authors:  Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism?

Authors:  Lamotte Guillaume; Agostini Denis
Journal:  J Nucl Cardiol       Date:  2015-12-07       Impact factor: 5.952

3.  Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations.

Authors:  Anna De Rosa; Teresa Pellegrino; Sabina Pappatà; Maria Teresa Pellecchia; Silvio Peluso; Francesco Saccà; Paolo Barone; Alberto Cuocolo; Giuseppe De Michele
Journal:  J Nucl Cardiol       Date:  2015-12-01       Impact factor: 5.952

Review 4.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

Review 5.  Pathologic and therapeutic implications for the cell biology of parkin.

Authors:  Rakshita A Charan; Matthew J LaVoie
Journal:  Mol Cell Neurosci       Date:  2015-02-17       Impact factor: 4.314

Review 6.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

7.  Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion.

Authors:  Sangwoo Ham; Seung Pil Yun; Hyojung Kim; Donghoon Kim; Bo Am Seo; Heejeong Kim; Jeong-Yong Shin; Mohamad Aasif Dar; Gum Hwa Lee; Yun Il Lee; Doyeun Kim; Sunghoon Kim; Hee-Seok Kweon; Joo-Ho Shin; Han Seok Ko; Yunjong Lee
Journal:  Sci Transl Med       Date:  2020-11-11       Impact factor: 17.956

Review 8.  Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?

Authors:  Tilo Kunath; Ammar Natalwala; Claire Chan; Yixi Chen; Benjamin Stecher; Martin Taylor; Sadaquate Khan; Miratul M K Muqit
Journal:  Eur J Neurosci       Date:  2019-01-23       Impact factor: 3.386

Review 9.  Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease.

Authors:  Daniel Aghaie Madsen; Sissel Ida Schmidt; Morten Blaabjerg; Morten Meyer
Journal:  Cells       Date:  2021-01-31       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.